Geratherm Medical AG (XTER:GME) 5-Year EBITDA Growth Rate : 5.70% (As of Jun. 2023)

View and export this data going back to 2000. Start your Free Trial

What is Geratherm Medical AG 5-Year EBITDA Growth Rate?

Geratherm Medical AG's EBITDA per Share for the three months ended in Jun. 2023 was €0.00.

During the past 12 months, Geratherm Medical AG's average EBITDA Per Share Growth Rate was -3.90% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was 6.20% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 5.70% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 0.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Geratherm Medical AG was 39.10% per year. The lowest was -23.40% per year. And the median was 1.30% per year.

Competitive Comparison of Geratherm Medical AG's 5-Year EBITDA Growth Rate

For the Medical Devices subindustry, Geratherm Medical AG's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Geratherm Medical AG's 5-Year EBITDA Growth Rate Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Geratherm Medical AG's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Geratherm Medical AG's 5-Year EBITDA Growth Rate falls into.

Geratherm Medical AG 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Geratherm Medical AG (XTER:GME) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Geratherm Medical AG 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Geratherm Medical AG's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Geratherm Medical AG (XTER:GME) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Geratherm Medical AG (XTER:GME) » Definitions » 5-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

GME:Germany

Address

Fahrenheitstrasse 1, Geratal, DEU, 99331

Website

https://www.geratherm.com

Geratherm Medical AG is a Germany-based medical technology company. The firm operates through four segments: Healthcare Diagnostic, Medical Warming Systems, Cardio/Stroke and Respiratory. Healthcare Diagnostic segment which generates majority revenue provides analog and digital products for measuring body temperature, blood pressure monitors and other products for measuring temperature, as well as related accessories. Medical Warming Systems offers solutions for temperature management at all stages in the pre-clinical and clinical care of the patients, such as rescue situations and operations. Cardio/Stroke segment comprises products for preventing strokes. The Respiratory segment focuses on the development and production of products for pulmonary functional diagnostics.

Executives